About HLA class II histocompatibility antigen, DR alpha chain
HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) is a protein
from Homo sapiens identified by UniProt accession
P01903, 254 residues long.
MolForge cross-references it against 0 known binders and
323 disease associations.
Target properties
| Protein name | HLA class II histocompatibility antigen, DR alpha chain |
|---|
| UniProt accession | P01903 |
|---|
| Gene | HLA-DRA |
|---|
| Organism | Homo sapiens |
|---|
| Length | 254 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (323)
Diseases linked to this target (Open Targets).
- Parkinson disease · score 0.38
- blood protein measurement · score 0.35
- primary biliary cirrhosis · score 0.34
- multiple sclerosis · score 0.33
- type 1 diabetes mellitus · score 0.30
- complement C4 measurement · score 0.29
- response to vaccine · score 0.28
- systemic scleroderma · score 0.28
- apolipoprotein B measurement · score 0.28
- mosquito bite reaction itch intensity measurement · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P01903-F1 | alphafold | PREDICTED | 89.17 | — |
Amino-acid sequence (254 residues)
MAISGVPVLG FFIIAVLMSA QESWAIKEEH VIIQAEFYLN PDQSGEFMFD FDGDEIFHVD MAKKETVWRL EEFGRFASFE AQGALANIAV DKANLEIMTK RSNYTPITNV PPEVTVLTNS PVELREPNVL ICFIDKFTPP VVNVTWLRNG KPVTTGVSET VFLPREDHLF RKFHYLPFLP STEDVYDCRV EHWGLDEPLL KHWEFDAPSP LPETTENVVC ALGLTVGLVG IIIGTIFIIK GLRKSNAAER RGPL
Explore HLA class II histocompatibility antigen, DR alpha chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets